RECRUITING

Acetazolamide for Treatment Resistant Schizophrenia

Talk to us

Conditions

SchizophreniaSchizo Affective Disorderacetazolamide

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a double blind adjunctive randomized controlled trial for schizophrenia using acetazolamide.

Official Title

A Randomized Controlled Trial of Acetazolamide for Patients With Treatment Resistant Schizophrenia

Quick Facts

Study Start:2022-02-01
Study Completion:2025-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04887792

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 55 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Written informed consent.
  2. * Both genders, ages 18-55 years (older patients may not tolerate high ACZ dose).
  3. * PANSS total score \> 60 and Score \> 4 on one or more items of the 'positive' syndrome items (P1-P7), following treatment at therapeutic doses for 6 weeks with different APDs on 2 occasions.
  4. * Stable dose of antipsychotic drug (APD) for \> 1 month, continued throughout the study.
  5. * Not participating in another randomized controlled clinical trial (RCT).
  1. * Substance abuse in the past month/dependence past 6 months, (except nicotine).
  2. * History or current medical/neurological illnesses that may lead to unstable course, e.g., epilepsy.
  3. * Pregnancy.
  4. * Acetazolamide (ACZ) contraindications: hypersensitivity to ACZ; history of renal hyperchloremic acidosis; Addison's disease/adrenal failure; chronic closed angle-closure glaucoma.
  5. * Current or prior treatment with ACZ or history of hypersensitivity to ACZ.
  6. * Intellectual disability as defined in DSM 5.

Contacts and Locations

Study Contact

Vishwajit L Nimgaonkar, M.D., Ph.D.
CONTACT
412-246-6356
vishwajitNL@upmc.edu
Maribeth A Wesesky, BPS
CONTACT
4122957017
weseskyma@upmc.edu

Principal Investigator

Vishwajit L Nimgaonkar, M.D., Ph.D.
PRINCIPAL_INVESTIGATOR
University of Pittsburgh

Study Locations (Sites)

University of Pittsburgh
Pittsburgh, Pennsylvania, 15213
United States

Collaborators and Investigators

Sponsor: Vishwajit Nimgaonkar, MD PhD

  • Vishwajit L Nimgaonkar, M.D., Ph.D., PRINCIPAL_INVESTIGATOR, University of Pittsburgh

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-02-01
Study Completion Date2025-06-30

Study Record Updates

Study Start Date2022-02-01
Study Completion Date2025-06-30

Terms related to this study

Keywords Provided by Researchers

  • Schizophrenia
  • Schizo Affective Disorder
  • acetazolamide

Additional Relevant MeSH Terms

  • Schizophrenia
  • Schizo Affective Disorder